SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 2 — Focused Visit (Follow-up) — Audre Lorde

PatientAudre Lorde
Date of birth1981-02-18
IdentifiersMRN HR-ML016-SYN; SSN (made up) 000-16-2937
Document date2026-03-30
AuthorNaomi Fairweather, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Survivorship follow-up on the day of the medical oncology consultation. [S]

History of Present Illness

Ms. Lorde returns three weeks after her first visit here. She saw Dr. Lozano of medical oncology this morning. She has taken tamoxifen every day for five months. She has three or four hot flashes a day and is woken by one on one or two nights a week; she would rather manage them without another medicine if she can. Her periods continue every four to five weeks, a little lighter, with no bleeding between them. She has no leg swelling, chest pain, or breathlessness. The mastectomy scar is comfortable, and she has no arm heaviness or swelling. She is writing and walking daily and feels steady in mood. She is settled in her decisions after surgery: she chose a flat closure and does not want reconstruction or an external prosthesis. [S]

ElementDetail
Interval changeMedical oncology consultation this morning
TamoxifenFive months, taken daily
Vasomotor symptomsThree or four hot flashes a day; wakes one or two nights a week
GynecologicPeriods every four to five weeks; no intermenstrual bleeding
Arm and chest wallNo swelling, heaviness, or pain

Review of Systems

SystemResultFinding
ConstitutionalNegativeNo fever, weight loss, or unexplained tiredness
EndocrinePositiveHot flashes three or four times a day
GenitourinaryNegativeNo abnormal vaginal bleeding or discharge
CardiovascularNegativeNo leg swelling, calf pain, or chest pain
RespiratoryNegativeNo breathlessness or cough
MusculoskeletalNegativeNo bone pain; full use of the right arm
PsychiatricNegativeMood steady; sleeping well on most nights

7 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Tamoxifen 20 mg oral tablet, one tablet by mouth once daily, planned for at least five yearsOne tablet once dailyOral route2025-10-27activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-03-30Body height168cmS
2026-03-30Body weight72.4kgS
2026-03-30Body mass index (BMI) [Ratio]25.7kg/m2S
2026-03-30Systolic blood pressure122mm[Hg]S
2026-03-30Diastolic blood pressure76mm[Hg]S
2026-03-30Heart rate72/minS
2026-03-30Respiratory rate14/minS
2026-03-30Body temperature36.6CelS
2026-03-30Oxygen saturation in Arterial blood by Pulse oximetry99%S

Physical Exam

Vital signs recorded on 2026-03-30; see the Vital Signs section. [S]

SystemFinding
GeneralWell
Breasts and chest wallRight chest wall flat, scar healed, no nodules; left breast without masses
Lymph nodesNo axillary or supraclavicular nodes
ExtremitiesArm circumference 10 cm above the elbow 29.0 cm on each side; right shoulder full range of motion; calves soft and non-tender

Problems

ProblemClinical statusVerificationCodeProvenance
Invasive ductal carcinoma of the upper outer quadrant of the right breast, stage IA (pT1c pN0(sn) M0), grade 2, estrogen and progesterone receptor positive, HER2 negative, recurrence score 14; treated by right total mastectomy with sentinel node biopsy and on adjuvant tamoxifen; synthetic modern counterpart of the documented 1978 breast cancer and mastectomyactiveconfirmed C50.411S — Synthetic tumor details and treatment; the diagnosis and the mastectomy are documented (D), but no tumor details from her lifetime are used.
Estrogen receptor positive status of the breast cancer (ER 90 percent, PR 60 percent)activeconfirmed Z17.0S — Synthetic receptor result; no receptor status from her lifetime is known.
Absence of the right breast after mastectomy with flat closure; she chose not to have reconstruction and not to wear an external prosthesisactiveconfirmed Z90.11S — Synthetic coding of the documented mastectomy; the decision about a prosthesis echoes her documented choice and is respected as her own.
Long-term use of tamoxifen as adjuvant endocrine therapyactiveconfirmed Z79.810S — Synthetic treatment status.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ExaminationCancer-related history and physical examinationEvery 3 to 6 months for the first 3 yearsCompleted todayNo symptoms or signs of recurrence; chest wall and left breast normal
Medication safetyTamoxifen adherence and side effectsEvery visitCompleted todayTaken daily for five months; no missed doses
SurveyVasomotor symptom assessmentPeriodically on endocrine therapyCompleted todayThree or four hot flashes a day; non-drug measures started
ExaminationAbnormal vaginal bleeding inquiry on tamoxifenEvery visitCompleted todayNo bleeding between periods; yearly gynecologic assessment due at the autumn preventive visit
ExaminationVenous thromboembolism symptom inquiry on tamoxifenEvery visitCompleted todayNo leg swelling, calf pain, or breathlessness
Medication safetyInteracting medicines with tamoxifen (strong CYP2D6 inhibitors)At each medicine changeCompleted todayNo interacting medicine; if a hot-flash medicine is needed, venlafaxine rather than paroxetine or fluoxetine
ExaminationLymphedema assessment and risk-reduction counselingEvery visitCompleted todayNo swelling; arm circumferences equal; risk is low after sentinel node biopsy alone; counseled to report heaviness or swelling
SurveyDistress, depression, and anxiety screen (PHQ-9 and GAD-7)At periodic intervalsUp to datePHQ-9 4 and GAD-7 3 three weeks ago; next at the three-month visit
SurveyFatigue, cognitive concerns, and sexual or vaginal symptomsAt each visit or periodicallyCompleted todayNo fatigue or memory concerns; no vaginal dryness or pain
LaboratoryRoutine blood counts, chemistry, liver tests, and tumor markers (CEA, CA 15-3, CA 27.29)Not recommended in asymptomatic stage I to III survivorsNot indicatedNo symptoms to prompt testing; none ordered
ImagingCT, bone scan, PET, or other imaging for distant spreadNot recommended in asymptomatic survivorsNot indicatedNo symptoms; not ordered
ImagingDiagnostic mammogram of the left breastYearly after mastectomyDueIn September, one year after the diagnostic mammogram
ImagingBreast MRIYearly only if high-risk criteria are met (BRCA1 or BRCA2, chest radiation at 10 to 30, lifetime risk 20 percent or more)Not indicatedNo high-risk criterion known; to be revisited if germline testing finds a pathogenic variant
ImagingBone density (DXA)Every 2 years on an aromatase inhibitor, on tamoxifen with ovarian suppression, or after chemotherapy-induced menopauseNot indicatedPremenopausal on tamoxifen alone; bone health by diet, vitamin D, and weight-bearing exercise
ImagingEchocardiogram (LVEF)During and after trastuzumab; after anthracycline as indicatedNot indicatedNo trastuzumab or anthracycline given
ReferralGermline genetic testing at diagnosis, for breast cancer diagnosed at 65 or youngerOnce, at diagnosisDeferredNot offered at diagnosis by her previous care team, a deviation from the guideline found at intake. No harm is known: the result would not have changed her surgery, which she chose, but it could change surveillance and the advice to relatives. Corrective action: genetic counseling requested today, as Dr. Lozano advised
ReferralGenetic counselingOnceReferredRequest sent today; on the waiting list
ReferralMedical oncologyShared survivorship careCompleted todaySeen this morning; recommendations in the consultation note
Self-managementHealthy lifestyle counselingEvery visitCompleted todayWalking about 30 minutes most days; goal of 150 minutes a week plus strength exercise twice a week; alcohol rarely; never smoker

Goal progress:

Guideline basis: American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. CA Cancer J Clin 2016;66(1):43-73 (2016); Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update (2019); Germline Testing in Patients With Breast Cancer: ASCO-Society of Surgical Oncology Guideline. J Clin Oncol 2024 (2024); CMID: Clinical Monitoring Intelligence Database, breast cancer monograph (2026)

Follow-up: Survivorship visit in three months with PHQ-9 and GAD-7. Genetic counseling when offered. Call for abnormal bleeding, leg swelling, a new lump, bone pain, or arm swelling. Next scheduled visit 2026-06-29: three-month survivorship visit on tamoxifen. [S]